George Ntaios1, Gregory Y H Lip2, Dimitris Lambrou2, Vasileios Papavasileiou2, Efstathios Manios2, Haralampos Milionis2, Konstantinos Spengos2, Konstantinos Makaritsis2, Konstantinos Vemmos2. 1. From the Department of Medicine (G.N., D.L., V.P., K.M.), Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece; University of Birmingham Centre for Cardiovascular Sciences (G.Y.H.L.), City Hospital, Birmingham, UK; Department of Clinical Therapeutics (E.M., K.V.), Medical School of Athens, Alexandra Hospital, Athens; Department of Medicine (H.M.), Ioannina University Hospital, School of Medicine, University of Ioannina; and Department of Neurology (K.S.), Eginition Hospital, University of Athens Medical School, Greece. gntaios@med.uth.gr. 2. From the Department of Medicine (G.N., D.L., V.P., K.M.), Larissa University Hospital, School of Medicine, University of Thessaly, Larissa, Greece; University of Birmingham Centre for Cardiovascular Sciences (G.Y.H.L.), City Hospital, Birmingham, UK; Department of Clinical Therapeutics (E.M., K.V.), Medical School of Athens, Alexandra Hospital, Athens; Department of Medicine (H.M.), Ioannina University Hospital, School of Medicine, University of Ioannina; and Department of Neurology (K.S.), Eginition Hospital, University of Athens Medical School, Greece.
Abstract
OBJECTIVE: We aimed to investigate the association between leukoaraiosis and long-term risk of stroke recurrence adjusting for clinical scores developed and validated for the prediction of stroke risk, such as CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or TIA) and CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category). METHODS: Study population was derived from the Athens Stroke Registry and was categorized in 2 subgroups according to the presence of atrial fibrillation (AF). Cox proportional hazards analysis was performed to assess the independent predictors of stroke recurrence. To investigate whether leukoaraiosis adds to the prognostic accuracy of CHADS2 and CHA2DS2-VASc scores, we used the likelihood ratio test. Overall model assessment was performed with Nagelkerke R(2) and Harrell C statistic. Kaplan-Meier analyses were also performed. RESULTS: Among 1,892 patients, there were 320 (16.9%) with leukoaraiosis and 670 (35.4%) with AF. In the Kaplan-Meier analysis, there was significant difference in cumulative probability of stroke recurrence between patients with and without leukoaraiosis in the non-AF group (p < 0.01), but not in the AF group (p = 0.46). On Cox multivariate analysis, leukoaraiosis was found to be a significant independent predictor of stroke recurrence only in the non-AF group, in the models adjusting for CHADS2 (hazard ratio: 1.86, 95% confidence interval: 1.35-2.56) and CHA2DS2-VASc (hazard ratio: 1.82, 95% confidence interval: 1.32-2.51) scores. Leukoaraiosis was not a predictor of stroke recurrence in the AF group. Leukoaraiosis did not improve the predictive accuracy of the 2 scores, whether in the non-AF group (Harrell C statistic: 0.56 vs 0.59 [p = 0.31] for the model including CHADS2; 0.56 vs 0.59 [p = 0.44] for the model including CHA2DS2-VASc) or the AF group (Harrell C statistic: 0.63 vs 0.62 for the model including CHADS2; 0.64 vs 0.64 for the model including CHA2DS2-VASc). CONCLUSIONS: Leukoaraiosis is an independent predictor of stroke recurrence in non-AF stroke patients. However, leukoaraiosis did not increase the accuracy of the CHADS2 and CHA2DS2-VASc scores to predict stroke recurrence in AF or non-AF stroke patients.
OBJECTIVE: We aimed to investigate the association between leukoaraiosis and long-term risk of stroke recurrence adjusting for clinical scores developed and validated for the prediction of stroke risk, such as CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke or TIA) and CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or TIA, vascular disease, age 65-74 years, sex category). METHODS: Study population was derived from the Athens Stroke Registry and was categorized in 2 subgroups according to the presence of atrial fibrillation (AF). Cox proportional hazards analysis was performed to assess the independent predictors of stroke recurrence. To investigate whether leukoaraiosis adds to the prognostic accuracy of CHADS2 and CHA2DS2-VASc scores, we used the likelihood ratio test. Overall model assessment was performed with Nagelkerke R(2) and Harrell C statistic. Kaplan-Meier analyses were also performed. RESULTS: Among 1,892 patients, there were 320 (16.9%) with leukoaraiosis and 670 (35.4%) with AF. In the Kaplan-Meier analysis, there was significant difference in cumulative probability of stroke recurrence between patients with and without leukoaraiosis in the non-AF group (p < 0.01), but not in the AF group (p = 0.46). On Cox multivariate analysis, leukoaraiosis was found to be a significant independent predictor of stroke recurrence only in the non-AF group, in the models adjusting for CHADS2 (hazard ratio: 1.86, 95% confidence interval: 1.35-2.56) and CHA2DS2-VASc (hazard ratio: 1.82, 95% confidence interval: 1.32-2.51) scores. Leukoaraiosis was not a predictor of stroke recurrence in the AF group. Leukoaraiosis did not improve the predictive accuracy of the 2 scores, whether in the non-AF group (Harrell C statistic: 0.56 vs 0.59 [p = 0.31] for the model including CHADS2; 0.56 vs 0.59 [p = 0.44] for the model including CHA2DS2-VASc) or the AF group (Harrell C statistic: 0.63 vs 0.62 for the model including CHADS2; 0.64 vs 0.64 for the model including CHA2DS2-VASc). CONCLUSIONS:Leukoaraiosis is an independent predictor of stroke recurrence in non-AF strokepatients. However, leukoaraiosis did not increase the accuracy of the CHADS2 and CHA2DS2-VASc scores to predict stroke recurrence in AF or non-AF strokepatients.
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Ahmet Bagci; Noam Alperin; Ralph L Sacco; Mitchell S V Elkind; Clinton B Wright Journal: J Am Geriatr Soc Date: 2017-11-20 Impact factor: 5.562
Authors: George Ntaios; Gregory Y H Lip; Konstantinos Vemmos; Eleni Koroboki; Efstathios Manios; Anastasia Vemmou; Ana Rodríguez-Campello; Elisa Cuadrado-Godia; Jaume Roquer; Valentina Arnao; Valeria Caso; Maurizio Paciaroni; Exuperio Diez-Tejedor; Blanca Fuentes; Josefa Pérez Lucas; Antonio Arauz; Sebastian F Ameriso; Lucía Pertierra; Maia Gómez-Schneider; Maximiliano A Hawkes; Fabio Bandini; Beatriz Chavarria Cano; Ana Maria Iglesias Mohedano; Andrés García Pastor; Antonio Gil-Núñez; Jukka Putaala; Turgut Tatlisumak; Miguel A Barboza; George Athanasakis; Fotios Gioulekas; Konstantinos Makaritsis; Vasileios Papavasileiou Journal: Neurology Date: 2017-07-07 Impact factor: 9.910
Authors: Francesco Moroni; Enrico Ammirati; Maria A Rocca; Massimo Filippi; Marco Magnoni; Paolo G Camici Journal: Int J Cardiol Heart Vasc Date: 2018-05-14
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Ahmet Bagci; Noam Alperin; Ralph L Sacco; Mitchell S V Elkind; Clinton B Wright Journal: Front Aging Neurosci Date: 2017-09-20 Impact factor: 5.750
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon Moon; Janet DeRosa; Ralph Sacco; Mitchell S V Elkind; Clinton B Wright Journal: PLoS Med Date: 2018-03-20 Impact factor: 11.069